MG-001 phase 2b
81 evidence topics · 11 sources
Objective
Objective: efficacy and safety of Descartes-08 versus placebo in generalized MG
Registered objective of the phase 2b study
Objective as stated in the September 2025 congress poster
Location and study date
Settings and countries
“MG-001 part 3 was a phase 2b, randomized, double-blind, placebo-controlled trial of Descartes-08 in patients with MGFA class II–IV gMG, conducted in academic medical centers and community neurology clinics in North America and Türkiye (ClinicalTrials.gov identifier: NCT04146051).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The trial was approved by regulatory authorities in each country (USA, Canada and Türkiye), the central and local institutional review boards in the USA (Western Institutional Review Board-Copernicus Group, WCG IRB, Puyallup, WA), and the ethics committee at each site in other countries (the research ethics boards at the University of Toronto and the University of Alberta, as well as the ethics committee at Istanbul University).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Screening period, November 2022 to January 2024
“A total of 50 participants were screened for eligibility in this study (MG-001 part 3) between November 10, 2022, and January 15, 2024 (Fig. 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Part 3 was added to the MG-001 study protocol in amendment v3.0 (August 1, 2022).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study design
Randomized, double-blind, placebo-controlled design with 12-month follow-up
“In this phase 2b, double-blind, placebo-controlled trial, eligible patients with gMG who tested negative for autoantibodies to MuSK were randomized 1:1 to receive six once-weekly intravenous infusions of Descartes-08 or placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study included a 12-month follow-up period to assess the efficacy of treatment using the MG Composite (MGC), MG Activities of Daily Living (MG-ADL) and Quantitative MG (QMG) scores.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Leukapheresis before randomization and placebo manufacture
“All eligible participants underwent leukapheresis and had a Descartes-08 lot and an acellular placebo lot manufactured under Good Manufacturing Practice conditions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following the successful manufacturing of the autologous product, participants enrolled in part 3 were randomized 1:1 to receive either Descartes-08 or placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Randomization and allocation concealment
“Randomization was performed centrally using a computer-generated permuted-block scheme without stratification (Mathematica v13.0, Wolfram Research).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Block sizes were varied and concealed from site personnel to maintain unpredictability in allocation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The random allocation sequence was generated by the study statistician and implemented centrally at the autologous lot manufacturing stage by sponsor staff who were otherwise uninvolved in the study conduct.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blinding through the month 3 primary endpoint assessment
“Participants, study team members and all sponsor staff involved in the treatment or clinical evaluation of the patients, as well as in the review or analysis of data, were blinded to the treatment assignment until after the primary endpoint assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Blinding of study personnel, clinic staff and participants during infusion was maintained using opaque coverings for the infusion bag and tubing, which were identical between Descartes-08 and placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Blinded follow-up occurred at 2 weeks (month 2) and 6 weeks (month 3) after the last infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Open-label crossover after month 3 and 12-month follow-up
“Both the study teams and participants were blinded to the treatment assignment through the month 3 visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After the primary endpoint assessment at month 3, participants randomized to placebo had the option to cross over to Descartes-08, which was administered under an open-label protocol.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All participants were followed up for 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rescue therapy
“Participants who demonstrated a ≥3-point worsening of the MG-ADL score from baseline or showed signs of an impending myasthenic crisis could receive rescue therapy, which, for those randomized to placebo, included Descartes-08.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Independent study monitoring committee
Protocol amendments: enrollment cap, primary endpoint, and primary efficacy population
“Major amendments include v3.2 (October 17, 2023), which increased the enrollment cap to 50; v3.3 (January 8, 2024), which specified a 5-point reduction in the MGC score at month 3 as the primary endpoint; and v4.2 (June 19, 2024), which defined the primary efficacy population and outlined the use of the estimand framework for intercurrent events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Inclusion criteria: age, MGFA class, background immunosuppression, and corticosteroid dose
“All participants were required to meet the following inclusion criteria: ≥18 years of age; a diagnosis of gMG, defined as MGFA clinical class III or IV (part 1; dose escalation) or class II–IV (parts 2–4) at the time of screening; use of concomitant immunosuppressive drugs deemed necessary by the investigator; daily dose of corticosteroids of ≤40 mg per day of prednisone equivalent, with a stable dose for a minimum of 4 weeks before the baseline visit” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“participants must have an MG-ADL total score of ≥6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inclusion criteria: seropositive and seronegative cohorts
“for the seropositive cohort only: MG-specific antibody titer must be above the reference laboratory’s upper limit of normal and documented within 10 years of screening (patients who were MuSK or LRP4 autoantibody-positive were allowed to be enrolled in parts 1 and 2 only and were not eligible for this trial)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“for the seronegative cohort only: unequivocal response to cholinesterase inhibitors and abnormal repetitive nerve stimulation or increased jitter (participants must not have another neuromuscular disease that may cause increased jitter and must have a negative congenital myasthenic syndrome panel)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants who tested positive for MuSK autoantibodies were excluded from the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion criteria: recent IVIg, plasma exchange, B-cell therapy, and biologics
“intravenous infusion of immunoglobulin or plasma exchange within 4 weeks before the baseline (day 1) visit; treatment with rituximab or ocrelizumab within 12 months before the baseline (first infusion) visit; treatment with calcineurin inhibitors (for example, tacrolimus, cyclosporine, cyclophosphamide), FcRn antagonists and/or other biologics within 3 weeks before the planned leukapheresis and within 8 weeks before the baseline (first infusion) visit; initiation of eculizumab treatment within 8 weeks before the baseline (first infusion) visit (patients who had been receiving eculizumab for more than 8 weeks and met other criteria for enrollment were eligible for treatment on the trial)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion criteria: immunodeficiency, infection, malignancy, and live vaccines
“history of primary immunodeficiency or organ or allogeneic bone marrow transplant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“active tuberculosis or a positive QuantiFERON test at screening” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“a history of malignancy that required treatment in the past 3 years, except for successfully treated squamous cell and/or basal cell carcinoma of the skin and/or breast or colon cancer that was surgically removed and did not require adjuvant chemotherapy or radiotherapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“receipt of a live vaccination within 4 weeks before baseline (day 1) or intent to receive live vaccination during the study” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Six once-weekly infusions of Descartes-08 or placebo with 12-month follow-up
Protocol dose and comparison with background immunosuppression
Study outcomes
Rationale for using MGC response as the primary endpoint
Primary endpoint: 5-point or greater MGC decrease at month 3
“The primary endpoint was the proportion of participants who demonstrated a ≥5-point decrease in the MGC score at month 3 compared to baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MGC scale is a ten-item, 60-point weighted instrument composed of both patient-reported and provider-assessed items, which are themselves components of two other scales (MG-ADL and QMG).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MGC was recommended by the 2000 MGFA Task Force for MG trials” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A 3-point change in the MGC score is considered clinically meaningful.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Change of the primary outcome from MG-ADL to MGC, January 2024
“On January 8, 2024, after the enrollment of 44 participants and before the unblinding of data and database lock, the steering committee of the trial, in consensus with the study monitoring committee, decided to implement a change in the primary outcome: from the MG-ADL score to the MGC score (previously a secondary outcome).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The original primary outcome (MG-ADL score) was changed to a secondary outcome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This decision was made based on the recommendations of the 2000 MG Foundation of America (MGFA) Task Force” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“with plans to use the MGC score as the primary outcome in a subsequent phase 3 trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consequently, the primary endpoint for this phase 2b study was a ≥5-point improvement in the MGC score at month 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for the 5-point threshold: higher-than-expected baseline MGC scores
“Notably, the 5-point improvement cutoff is higher than the 3-point decrease in the MGC score considered to be clinically meaningful.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This threshold was chosen to account for the higher-than-expected baseline MGC score compared to the scores observed in the MGC validation set” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for the 5-point threshold: company statement, July 2024
Registered primary outcome measure
Secondary efficacy endpoints
“Secondary efficacy endpoints were the mean change from baseline in MGC, MG-ADL, QMG and MG-QoL-15r scores at each postinfusion visit (months 2, 3, 4, 6, 9 and 12), as well as the proportion of participants with ≥2–8-point improvements in MG-ADL, QMG and MGC scores at each postinfusion visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered secondary outcomes: 6-point responses and crossover participants
MG-ADL: instrument and clinically meaningful change
“The MG-ADL scale is an eight-item, 24-point, patient-reported instrument that assesses the effects of gMG on daily functioning” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A 2-point change is considered clinically meaningful.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
QMG: instrument and clinically meaningful change
“The QMG scale is a standardized, 39-point scoring system consisting of 13 provider-assessed items, which include hand-grip strength and forced vital capacity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A 3-point change is considered clinically meaningful.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety endpoints
“Safety endpoints included the occurrence of AEs and SAEs from the time of apheresis through month 12, as well as laboratory values and vital signs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AEs were coded using CTCAE version 5.0.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size and power calculation
“We estimated that 15 participants per treatment group would provide 80% power to detect a difference of 47% in responders between Descartes-08 and placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Calculations assumed 87% responders in the Descartes-08 group and 40% responders in the placebo group, based on a two-sample proportion test for independent samples to detect a difference in proportions at the 0.05 (nondirectional) level of significance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To account for screen failures and missed randomization due to insufficient cells manufactured, we enrolled up to 50 participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants analyzed: safety population (36) and primary efficacy population (26)
“Thirty-six participants were deemed eligible and randomized to receive Descartes-08 (n = 20) or placebo (n = 16), comprising the safety population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-six participants were enrolled in an academic institution and had at least one postinfusion follow-up available, and they comprised the primary efficacy population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients (n = 26) were randomly allocated to receive once-weekly intravenous infusions of Descartes-08 (n = 15) or placebo (n = 11) over 6 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants analyzed: company topline counts, July 2024, superseded in January 2026
Description of analysis sets
Primary efficacy (mITT) population restricted to academic-center participants
“Primary efficacy analyses were performed on a modified intention-to-treat (mITT) population, comprising all participants enrolled at an academic medical center who had at least one postbaseline follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline demographics and safety endpoints (that is, type and frequency of AEs) were analyzed in all enrolled participants using descriptive statistics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Protocol definitions of the mITT, ITT, and per-protocol populations
Primary endpoint analysis and handling of rescue and missing data
“The primary endpoint—the response status at month 3 (day 85), in which responders were defined as those who had a reduction of 5 points or more in their MGC total score compared to baseline—was analyzed using a two-independent-sample proportion test at a two-sided 5% significance level; a Wald chi-squared test was used to determine whether there was a significant association between the treatment group and the response status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants who required rescue medication before day 85 had their MGC scores set to missing; these were imputed using baseline observation carried forward, with the response status set to nonresponder.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All other missing data were imputed using multiple imputation, assuming data were missing at random.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This was not required for the participants in the mITT population, as the data were complete.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subgroup analyses
“Subgroup analyses were carried out to determine whether there was a difference in the response between participants who were anti-AChR antibody-positive and those who were anti-AChR antibody-negative, between those with early- and late-onset disease, between those with and without prior exposure to complement and FcRn inhibitors, and between those who did and did not develop a fever.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The difference in the proportion of responders was assessed, and the Wald chi-squared test for association between response status and subgroup was performed separately within each treatment group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Follow-up efficacy dataset after month 3, company definition
Overall poster population combining per-protocol and mITT participants
Results
Participant disposition
Screening, leukapheresis, and manufacturing failures before randomization
“Of those, 45 participants met the inclusion criteria and underwent a single leukapheresis with a median of six doses produced (range, four to six doses).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In accordance with the protocol, 9 of the 45 participants (20.0%) were not randomized; they received Descartes-08 under an open-label protocol because they failed to meet the therapeutic dose requirements for treatment, as fewer than six doses were manufactured (results to be reported separately).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Withdrawal after two infusions
“One of the participants randomized to Descartes-08 withdrew from the study for reasons other than safety or efficacy after two infusions, and subsequent labs were not analyzed; therefore, 35 total randomized patients were analyzed in the correlative/mechanistic study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Placebo participants crossed over to Descartes-08 after month 3
Month 12 follow-up completion and loss to follow-up, March 2025 data cutoff
Baseline characteristics
Baseline demographics and disease characteristics, mITT population
Previous and ongoing MG therapies, mITT population
Disease severity and antibody status, mITT population
“Overall, 11 (73.3%) participants in the Descartes-08 group and 8 (72.7%) participants in the placebo group had MGFA class III or IV MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, two participants with MGFA class IIa MG were enrolled in the placebo group, whereas no participants with MGFA class IIa MG were enrolled in the Descartes-08 group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of these, 19 (73.1%) were AChR autoantibody-positive, 1 (3.8%) was LRP4 autoantibody-positive and 6 (23.1%) were triple seronegative.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Differences in concomitant therapy and prior biologic exposure between groups, mITT population
“The proportion of participants reporting concomitant use of nonsteroidal immunosuppressants was lower in the Descartes-08 group than in the placebo group (n = 6, 40.0% versus n = 8, 73.0%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median daily dose of concomitant prednisone equivalent was 20 mg (range, 5–25 mg) in the Descartes-08 group and 10 mg (range, 6–20 mg) in the placebo group, with no changes in dosing allowed before month 6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Almost half of the participants in the Descartes-08 group (n = 7/15, 40.0%) and 6 of 11 (54.5%) participants in the placebo group received prior or ongoing complement inhibitors, and a third of participants in both groups received an FcRn inhibitor as prior treatment for their MG, indicating the refractory nature of the disease in a large proportion of study participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics of all randomized participants (safety population)
| Characteristic | Placebo (n=16) | Descartes-08 (n=20) |
|---|---|---|
| Female, % (n) | “62.5 (10)” | “55.0 (11)” |
| Age, years, mean (SD) | “57.8 (14.4)” | “59.4 (14.7)” |
| Median duration of disease, years (range) | “5 (1–23)” | “6 (0–26)” |
| MGFA class III at screening, % (n) | “68.8 (11)” | “70.0 (14)” |
| AChR+, % (n) | “75.0 (12)” | “80.0 (16)” |
| Sero-negative, % (n) | “25.0 (4)” | “15.0 (3)” |
| Diagnosis of thymoma, % (n) | “31.3 (5)” | “10.0 (2)” |
| Previous thymectomy, % (n) | “50.0 (8)” | “30.0 (6)” |
| Previous FcRn antagonist, % (n) | “37.5 (6)” | “30.0 (6)” |
| Previous complement inhibitor, % (n) | “37.5 (6)” | “15.0 (3)” |
Efficacy results
Primary endpoint and month 3 score changes, mITT population (Descartes-08 n = 15; placebo n = 11)
| MGC responder comparison at month 3 | Value |
|---|---|
| Difference in proportions (95% CI) | “0.39 (0.01–0.77)”View highlighted excerpt for this quote |
| P value | “0.0472”View highlighted excerpt for this quote |
Primary endpoint met at month 3, mITT population
“At month 3, the proportion of patients achieving a ≥5-point improvement in the MGC score was significantly higher for those treated with Descartes-08 compared to placebo in the overall population (66.7% (n = 10/15) versus 27.3% (n = 3/11), P = 0.0472) and in a subpopulation of those positive for autoantibodies to the acetylcholine receptor (63.6% (n = 7/11) versus 12.5% (n = 1/8), P = 0.0258).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Statistical significance was determined using a two-sided two-independent-sample proportion test.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary endpoint, mITT population: company topline, July 2024, superseded in January 2026
Primary endpoint, per-protocol population: company topline, July 2024
MGC response and MG-ADL change at month 3, poster overall population (31 participants) and AChR+ population (24 participants), September 2025
| Population | Descartes-08 responders | Placebo responders | P value |
|---|---|---|---|
| “A. Overall population (n=31)” | “(n=12/18)”“67%” | “(n=4/13)”“31%” | “p value: 0.048” |
| “B. AChR+ population (n=24)” | “(n=9/14)”“64%” | “(n=2/10)”“20%” | “p value: 0.031” |
MG-ADL and QMG changes through month 12, Descartes-08 group, mITT population (open-label follow-up)
“Responses deepened further during the follow-up for those in the Descartes-08 group, with the mean (s.d.) MG-ADL score reduction reaching −5.5 (1.1) at month 4 (day 113), which was maintained at month 12 (mean (s.d.) score, −4.8 (1.4)).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“QMG score reductions also continued throughout the follow-up period in the Descartes-08 group, reaching maximum improvement at month 12 (mean (s.d.) score, −6.0 (2.1)).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients treated with Descartes-08, the changes from baseline in mean MGC, MG-ADL and QMG scores at month 4 were −7.1, −5.5 and −4.8, respectively, with 83.0% of patients achieving a sustained and clinically meaningful response at month 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sustained clinically meaningful MG-ADL response at month 12, Descartes-08 group, mITT population
“In this phase 2b trial, the initial response rate was lower, with 10 of 15 participants (66.7%) achieving at least a 5-point improvement in the MGC score; however, all responses were maintained through 12 months, and 80.0% of participants had at least a clinically meaningful response 1 year after treatment, highlighting the durability of the effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sustained response at month 12: company update, December 2024, superseded in April 2025
Minimum symptom expression by month 6 and through month 12, Descartes-08 group, mITT population
“Minimum symptom expression (MSE), defined as an MG-ADL score of ≤1, was achieved by 33.3% (n = 4/12) of participants in the Descartes-08 group who reached month 6 of follow-up, and all individuals maintained this status through month 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of those achieving MSE, two participants were AChR autoantibody-positive and two were triple seronegative.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One participant in the placebo group who was triple seronegative achieved MSE status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, 33.0% of patients achieved minimum symptom expression (MSE) (MG-ADL score ≤1) by month 6, which was sustained through month 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Corticosteroid dose reduction and absence of therapy escalation through month 12
“Tapering of the prednisone dose was allowed at the investigators’ discretion after the month 6 visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After a median follow-up of 12 months, the median daily dose of orally administered prednisone equivalent in the Descartes-08 group was 9 mg (range, 2.5–20 mg), compared to 20 mg (range, 5–25 mg) at baseline—a 55.0% decrease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As there was no tapering allowed before month 6, the median dose in the placebo group remained unchanged throughout the follow-up at 10 mg (range, 6–20 mg).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“None of the participants randomized to Descartes-08 required escalation in MG therapies for the duration of the study, including intravenous infusion of immunoglobulin or plasma exchange.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Placebo responses and secondary endpoint significance
“There were several notable placebo responses during the early follow-up in the overall cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although these responses were waning by the primary endpoint assessment at month 3, they led to a lack of statistical significance in the study’s secondary outcomes of efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anti-AChR antibody levels at month 3
“While there was no difference between the groups in AChR autoantibody levels at month 3, an exploratory assay of all autoreactive antibodies showed a significant difference in the change at month 3 between Descartes-08 and placebo” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anti-AChR antibody levels at month 3: company presentation, October 2024, superseded in January 2026
Health-related quality of life and patient-reported outcomes
MG-QoL-15r, MG-ADL, and QMG change from baseline at month 3
“At month 3, the Descartes-08 group demonstrated substantially greater numerical and clinically meaningful reductions compared to the placebo group in the mean MG-ADL score (4.1 versus 1.6), QMG score (−3.9 versus −1.5) and MG-QoL-15r score (−5.7 versus −3.7) (Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All clinical outcome measures showed greater improvement in the Descartes-08 group compared with the placebo group, including patient-reported outcomes as measured by the MG-ADL score, objective improvements in patient strength as measured by the QMG score and the combination of the two measured by the MGC score.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MG-QoL-15r and other scales among Descartes-08 responders at month 3, July 2024
Safety results
Treatment-emergent adverse events, day 1 to month 3, safety population
“Treatment-emergent AEs from day 1 to month 3 for Descartes-08 and placebo” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Overall adverse events and grade 3 events, safety population
“Adverse event (AE) rates were similar between groups, with 17 of 20 (85.0%) participants in the Descartes-08 group and 13 of 16 (81.3%) participants in the placebo group reporting at least one AE during the study (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most AEs were mild or moderate (Common Terminology Criteria for AEs (CTCAE) grades 1–2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 20 participants in the safety population randomized to Descartes-08 and 16 participants randomized to placebo, 5 (25.0%) and 2 (12.5%), respectively, experienced a grade 3 AE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the Descartes-08 group, grade 3 AEs included a vasovagal reaction, a bacterial infection, fever, a herpes simplex virus (HSV) reactivation and a thromboembolic event (thrombosis of a central venous port placed several years before enrollment).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Meanwhile, grade 3 AEs reported in the placebo group included disease exacerbation and urinary tract infection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of these, only the case of fever was deemed possibly treatment-related.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serious adverse events and absence of grade 4 or 5 events, safety population
“There were no grade 4 or 5 (death) events in either group for the duration of the study (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Five serious AEs (SAEs) occurred in the Descartes-08 group (25.0%), while three SAEs occurred in the placebo group (18.8%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of these, three in the Descartes-08 group and one in the placebo group occurred after the first infusion: one each of an infusion-related reaction (IRR), syncope, HSV reactivation and hip fracture.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the three SAEs occurring after the first infusion in the Descartes-08 group, one (HSV reactivation) took place in an academic medical center, while two were reported in a community clinic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The only SAE deemed to be related to treatment was a grade 3 IRR manifesting as a fever of 40 °C, which started within 12 h of the fifth infusion and resolved within 48 h without the administration of tocilizumab or steroids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Infusion-related reactions: onset, management, and timing
“Generally, IRRs manifested as an acute onset of headache, nausea, fever, chills, arthralgia and myalgia within 8 h of infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In all but one case (the above-mentioned grade 3 IRR), IRRs were managed in an outpatient setting and resolved within 24 h without tocilizumab or steroid administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fevers, chills and myalgias typically occurred after doses two through five for participants who experienced these AEs, with four of six grade 2 fevers (39–40 °C) occurring after the second and third infusions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Postinfusion fever and cytokine release syndrome classification
“Due to the rapid onset and resolution of the severe fever without intervention, and in the absence of a concomitant increase in inflammatory markers commonly associated with cytokine release syndrome (CRS), this event was deemed to be an acute IRR.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In our study, most participants randomized to Descartes-08 developed postinfusion fevers for approximately half of the administered infusions, which could be interpreted as grade 1 CRS” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, several properties of the observed fevers do not support this interpretation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Infections and herpes simplex reactivation, safety population
“Infection rates were similar between the treatment groups, with more upper respiratory infections reported in the placebo group than in the Descartes-08 group (25.0% versus 15.0%), while more HSV reactivations were reported in the Descartes-08 group compared to the placebo group (15.0% versus 0%) (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, all HSV reactivations occurred in patients with a prior history of labial herpes who were on concomitant azathioprine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
B cells, immunoglobulins, and vaccine titers
“There was no difference in total circulating B cell levels between the Descartes-08 and placebo groups, and there were no cases of hypogammaglobulinemia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Serum levels of vaccine titers were similar between the two groups at month 3 and were maintained through month 12 in the Descartes-08 group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events after month 3 through month 12
Treatment-emergent adverse events, AChR antibody-positive participants
| Event, n (%) | Descartes-08 (n=16) | Placebo (n=12) |
|---|---|---|
| Any AE | “16 (100)” | “12 (100)” |
| Serious AE | “4 (25.0)” | “2 (16.7)” |
| Any AE leading to discontinuation of study drug | “1 (6.3)” | “1 (8.3)” |
| Any infusion-related reaction | “13 (81.3)” | “7 (58.3)” |
| Fever | “8 (50.0)” | “1 (8.3)” |
| Chills | “10 (62.5)” | “0” |
| Any infection | “6 (37.5)” | “5 (41.7)” |
| Herpes simplex reactivation | “2 (12.5)” | “0” |
Study limitations
Summary
- Sample size and power: the authors describe a phase 2 study with a limited sample size and 80% power to detect differences in the primary outcome, which makes comparisons of secondary outcomes descriptive. The power calculation assumed 15 participants per group, 87% responders with Descartes-08, and 40% with placebo. Numerical differences in secondary scores did not meet the hierarchical threshold for formal testing, and placebo responses during early follow-up led to a lack of statistical significance in the secondary efficacy outcomes.
- Analysis sets: of 45 participants who underwent leukapheresis, 9 (20.0%) were not randomized because fewer than six doses were manufactured. Of 36 randomized participants (safety population), the primary efficacy analysis included the 26 enrolled at an academic medical center with at least one postinfusion follow-up. The protocol specified sensitivity analyses in the overall ITT and per-protocol populations. The company's 2024 topline release reported the mITT population as 14 Descartes-08 and 12 placebo participants and the safety population as 19 and 17, where the published report gives 15 and 11, and 20 and 16.
- Change of primary endpoint: on January 8, 2024, after 44 participants had enrolled and before unblinding and database lock, the primary outcome was changed from the MG-ADL score to the MGC score, and the 5-point MGC threshold, chosen to account for higher-than-expected baseline MGC scores, exceeds the 3-point change considered clinically meaningful. The primary efficacy population was defined in protocol amendment v4.2 (June 19, 2024).
- Allocation and baseline imbalance: randomization had no stratification by site, and the authors state that this, the small sample, and the rate of participants not randomized likely led to unequal allocation. Disease duration and the rate of thymoma were higher in the placebo group, and triple seronegative participants (23.1%) were overrepresented compared with the general population, which the authors state affected the magnitude of the early placebo response. A transient effect of leukapheresis cannot be excluded.
- Subgroups: subgroup analyses compared participants by AChR antibody status, early- or late-onset disease (a prespecified analysis), prior exposure to complement and FcRn inhibitors, and development of fever, and an analysis of cell dose and MGC response was post hoc. The authors state that the small sample and heterogeneous population severely limit inferences about subgroups, and that the difference between biologic-naive and biologic-exposed participants may represent a true difference in biology, an artifact of a small sample size, or more treatment-refractory disease.
- Follow-up beyond month 3: all 11 placebo participants received open-label Descartes-08 after month 3, and month 4 to month 12 results are reported for the Descartes-08 group. As of a March 31, 2025 cutoff, the company reported that 12 of 15 Descartes-08 participants in the primary efficacy dataset completed month 12 and that 3 were lost to follow-up after month 3, 2 of whom were MGC responders at month 3.
- Other author-stated limitations: radioimmunoassay antibody testing may be insufficiently sensitive to changes in antibody subtype, mode of activity, and epitope; the protocol held prednisone stable until month 6 and allowed no change in nonsteroidal immunosuppressants; and fevers, chills, and myalgias were more common with Descartes-08 and may have affected the assessment of severity scales.
- Figures that differ between sources or within the report: sustained clinically meaningful response at month 12 is 83.0% in the abstract and 80.0% in the Discussion; minimum symptom expression is 33.0% in the abstract and 33.3% (4/12) in the Results; minimum symptom expression among biologic-naive participants is 55.60% in the abstract and 55.6% (5/9) in the Results, and the company's April 2025 release gives 57% (4/7) for biologic-naive participants with follow-up beyond month 3. The value −4.8 is reported both for the month-12 MG-ADL change and for the month-4 QMG change. The placebo MG-ADL change at month 3 in the AChR antibody-positive subgroup is 0.6 in the paper and −0.6 in a 2026 company slide presentation. The text reports prior or ongoing complement inhibitor use in the Descartes-08 group as “n = 7/15, 40.0%”.
Sample size, power, and descriptive secondary comparisons
“First, although randomized and placebo-controlled, this was a phase 2 study with a limited sample size and modest power (80%) to detect differences in the primary outcome, making any comparisons in secondary outcomes purely descriptive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Numerical differences between treatment group scores did not meet the hierarchical threshold for formal testing and were, therefore, not analyzed for statistical significance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In combination with the heterogeneous population enrolled, in terms of both gMG antibody type and prior treatment history, the small sample size also severely limits any inferences that can be made about the subgroups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Allocation and baseline imbalance
“The lack of stratification by site, combined with the small sample size and a higher-than-anticipated rate of enrolled participants not being randomized, likely led to unequal allocation between the active group and the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second, due to the small sample size, there was an imbalance in several disease characteristics, such as disease duration and the rate of thymoma, both of which were higher in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Overrepresentation of triple seronegative participants and possible leukapheresis effect
“Third, although a minority of participants (23.1%) were triple seronegative, this was still an overrepresentation compared to the general population, significantly affecting the magnitude of the early response observed in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, a transient effect of leukapheresis cannot be excluded, particularly as therapeutic plasma exchange is a common treatment option for refractory MG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antibody assay sensitivity
“Fourth, disease-specific antibodies were surveyed using radioimmunoassay in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, which, although in line with standard clinical practice, may be insufficiently sensitive to the changes in antibody subtype, mode of activity and epitope being targeted” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fixed background immunosuppression
“Fifth, the protocol mandated keeping the dose of prednisone stable until the month 6 visit (limiting the time available for dose de-escalation to 6 months) and did not allow any changes in the dose of nonsteroidal immunosuppressants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote